Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor

Arthritis and Rheumatism
X SuJ D Mountz

Abstract

To determine the effects of anti-tumor necrosis factor (anti-TNF) therapy in the inflammatory and autoimmune disease in motheaten (me/me) mice, which exhibit a Fas apoptosis signaling defect. Arthritis, pneumonitis, and mortality were analyzed in me/me mice treated with a novel, soluble, dimeric TNF receptor I (sTNFRI) molecule capable of high-affinity binding and neutralization of TNFalpha. Soluble TNFRI reduced serum levels of TNFalpha and led to a 2-fold increase in the lifespan of me/me mice, compared with the control treatment group. The treatment also reduced the development of the "motheaten" skin patches and alleviated pneumonitis and inflammatory lesions in the extremities of me/me mice compared with controls. However, the serum levels of IgM and IgM anti-double-stranded DNA autoantibody were comparable to those of untreated control mice. TNFalpha is an important cytokine involved in the pathogenesis of inflammatory disease in me/me mice, resulting in tissue damage and early mortality. Therapies directed at blocking TNF/TNFR interactions, such as the sTNFRI used in these experiments, may be effective in diseases associated with apoptosis defects leading to overutilization of the TNF/TNFR pathway.

References

Sep 1, 1975·The Journal of Heredity·M C Green, L D Shultz
Oct 1, 1992·The Journal of Experimental Medicine·T ZhouJ D Mountz
Jan 1, 1992·Annual Review of Immunology·P Vassalli
Dec 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·A AshkenaziD H Smith
Feb 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·J PlutzkyR D Rosenberg
Jan 1, 1991·Annual Review of Immunology·P L Cohen, R A Eisenberg
Oct 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P W GrayM Feldmann
Dec 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·J R GambleM A Vadas
Jan 1, 1995·The Journal of Experimental Medicine·M R AldersonD H Lynch
Feb 2, 1995·Nature·J DheinP H Krammer
Aug 1, 1995·British Journal of Cancer·D G AltmanK A Stepniewska
Aug 1, 1995·Clinical and Experimental Immunology·R N MainiM Feldmann
Jul 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·S KharbandaD Kufe
Sep 1, 1996·The Journal of Clinical Investigation·J WuJ D Mountz
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·U LorenzB G Neel
Mar 1, 1997·Arthritis and Rheumatism·L W MorelandW J Koopman

❮ Previous
Next ❯

Citations

Mar 20, 2001·Current Rheumatology Reports·J D MountzH G Zhang
Jan 16, 2010·Immunologic Research·Zhou ZhuTao Zheng
Sep 23, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ben A CrokerBruce Alan Beutler
Apr 17, 2001·Antimicrobial Agents and Chemotherapy·F NicolettiA Panerai
Dec 1, 1999·Annals of the Rheumatic Diseases·A N Theofilopoulos, B R Lawson
Oct 27, 2011·Journal of Biomedicine & Biotechnology·Yasunori IwataTakashi Wada
Jan 8, 2008·Arthritis Research & Therapy·Raimund W KinneGerd-R Burmester
Jan 30, 2008·Arthritis Research & Therapy·Martin Aringer, Josef S Smolen
Nov 30, 2000·Arthritis Research·R W KinneG R Burmester
Feb 11, 2015·Modern Rheumatology·Piotr PiotrowskiPaweł P Jagodziński
Jul 11, 2008·Expert Opinion on Drug Safety·Martin Aringer, Josef S Smolen
May 31, 2011·Autoimmunity Reviews·Martin Aringer, Josef S Smolen
Apr 6, 2005·Lupus·S Vasoo, G R V Hughes
May 11, 2000·Lupus·S ManziK Sutton-Tyrrell
Aug 16, 2000·Arthritis and Rheumatism·A Zonana-NacachM Petri
Jan 11, 2003·Arthritis and Rheumatism·Neil KramerElliot D Rosenstein
Nov 13, 2002·Arthritis and Rheumatism·Morris ReichlinMarianne Wolfson-Reichlin
Aug 23, 2017·Journal of Molecular Endocrinology·William J StanleyEsteban N Gurzov
Dec 21, 2000·Current Rheumatology Reports·M UrowitzI Bruce
Apr 29, 2008·Arthritis and Rheumatism·Lisabeth V ScalziH Lester Kirchner
Oct 7, 2005·Arthritis and Rheumatism·Karen H CostenbaderMatthew H Liang
Dec 12, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M B Borden, A L Parke
Sep 21, 2013·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Rayford R June, Lisabeth V Scalzi
May 1, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Masahiro SuganoNaoki Makino
Oct 18, 2001·Current Opinion in Rheumatology·J E Salmon, M J Roman
Oct 18, 2001·Current Opinion in Rheumatology·J Trager, M M Ward
Feb 19, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michael F DennyMariana J Kaplan
Apr 4, 2018·Molecular Neurobiology·Michael Maes, Andre F Carvalho
Jun 11, 1999·The American Journal of Physiology·R F LodatoF G Moody

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis